Literature DB >> 18773961

Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome.

X Altafaj1, J Ortiz-Abalia, M Fernández, M C Potier, J Laffaire, N Andreu, M Dierssen, C González-García, V Ceña, E Martí, C Fillat.   

Abstract

Transgenic mice overexpressing Dyrk1A (TgDyrk1A), a Down syndrome (DS) candidate gene, exhibit motor and cognitive alterations similar to those observed in DS individuals. To gain new insights into the molecular consequences of Dyrk1A overexpression underlying TgDyrk1A and possibly DS motor phenotypes, microarray studies were performed. Transcriptome analysis showed an upregulation of the NR2A subunit of the NMDA type of glutamate receptors in TgDyrk1A cerebellum. NR2A protein overexpression was also detected in TgDyrk1A cerebellar homogenates, in the synaptosome-enriched fraction and in TgDyrk1A primary cerebellar granular neuronal cultures (CGNs). In TgDyrk1A synaptosomes, calcium-imaging experiments showed a higher calcium uptake after NMDA stimulation. Similarly, NMDA administration promoted longer calcium transients in TgDyrk1A CGNs. Taken together, these results show that NMDA-induced calcium rise is altered in TgDyrk1A cerebellar neurons and indicate that calcium signaling is dysregulated in TgDyrk1A mice cerebella. These findings suggest that DYRK1A overexpression might contribute to the dysbalance in the excitatory transmission found in the cerebellum of DS individuals and DS mouse models.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18773961     DOI: 10.1016/j.nbd.2008.07.024

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  15 in total

Review 1.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

2.  The E3 ligase APC/C-Cdh1 is required for associative fear memory and long-term potentiation in the amygdala of adult mice.

Authors:  Joseph E Pick; Marcos Malumbres; Eric Klann
Journal:  Learn Mem       Date:  2012-12-14       Impact factor: 2.460

3.  Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.

Authors:  Jason Lockrow; Heather Boger; Heather Bimonte-Nelson; Ann-Charlotte Granholm
Journal:  Behav Brain Res       Date:  2010-04-02       Impact factor: 3.332

4.  Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine.

Authors:  Jonah J Scott-McKean; Alberto C S Costa
Journal:  Learn Mem       Date:  2011-11-18       Impact factor: 2.460

5.  Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.

Authors:  Yasushi Ogawa; Yosuke Nonaka; Toshiyasu Goto; Eriko Ohnishi; Toshiyuki Hiramatsu; Isao Kii; Miyo Yoshida; Teikichi Ikura; Hiroshi Onogi; Hiroshi Shibuya; Takamitsu Hosoya; Nobutoshi Ito; Masatoshi Hagiwara
Journal:  Nat Commun       Date:  2010-10-05       Impact factor: 14.919

6.  Identification of CHIP as a novel causative gene for autosomal recessive cerebellar ataxia.

Authors:  Yuting Shi; Junling Wang; Jia-Da Li; Haigang Ren; Wenjuan Guan; Miao He; Weiqian Yan; Ying Zhou; Zhengmao Hu; Jianguo Zhang; Jingjing Xiao; Zheng Su; Meizhi Dai; Jun Wang; Hong Jiang; Jifeng Guo; Yafang Zhou; Fufeng Zhang; Nan Li; Juan Du; Qian Xu; Yacen Hu; Qian Pan; Lu Shen; Guanghui Wang; Kun Xia; Zhuohua Zhang; Beisha Tang
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

7.  DYRK1A-mediated phosphorylation of GluN2A at Ser(1048) regulates the surface expression and channel activity of GluN1/GluN2A receptors.

Authors:  Cristina Grau; Krisztina Arató; José M Fernández-Fernández; Aitana Valderrama; Carlos Sindreu; Cristina Fillat; Isidre Ferrer; Susana de la Luna; Xavier Altafaj
Journal:  Front Cell Neurosci       Date:  2014-10-17       Impact factor: 5.505

Review 8.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

9.  Dyrk1A is dynamically expressed on subsets of motor neurons and in the neuromuscular junction: possible role in Down syndrome.

Authors:  Gloria Arque; Anna Casanovas; Mara Dierssen
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

10.  Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.

Authors:  Patrick T Udvardi; Karl J Föhr; Carolin Henes; Stefan Liebau; Jens Dreyhaupt; Tobias M Boeckers; Andrea G Ludolph
Journal:  Drug Des Devel Ther       Date:  2013-12-04       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.